Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

Lucia Masarova, Jorge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras-Gonzalez, Marina Konopleva, Srdan Verstovsek, Guillermo Garcia-Manero, Alessandra Ferrajoli, Tapan M. Kadia, Farhad Ravandi-Kashani, Gautam Borthakur, Sara DellaSala, Zeev Estrov, Elias J. Jabbour, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences